About Alzinova
Alzinova AB is a Swedish pharmaceutical enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.
Read more »Research
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers.
Press Releases
-
2019-12-02
Kristina Torfgård ny VD i Alzinova
-
2019-09-25
Alzinova inleder samarbete med världsledande producent av peptider
-
2019-09-03
Förändring av Alzinovas styrelsesammansättning
-
2019-06-04
Alzinova presenterar på Redeye Growth Day 10 juni 2018
-
2019-05-21
Uppdaterad tidsplan för klinisk studie, fas 1B
-
2019-05-20
Ledning och styrelse har utnyttjat optioner i Alzinova